Photocure ASA: Kjetil Hestdal steps down as CEO

Oslo, Norway, 26 June 2018: Photocure ASA (OSE: PHO), announces today that
President and Chief Executive Officer, Kjetil Hestdal, will step down effective
1 July 2018 as the company is entering a new growth phase with focus on global
commercial development. The Board of Directors has initiated a search for his
replacement and Chief Financial Officer Erik Dahl is appointed as interim CEO.
Mr. Hestdal will be available to the company until 30 December 2018.

"Photocure has developed a leading position in the field of bladder cancer and
is entering a period of accelerated growth, especially in the important U.S.
market, were we have a strong commercial focus to leverage on the opportunities
arising from the company's unique technology, products and excellent clinical
results. Kjetil has been instrumental in developing the company to this stage
with ambitions to become a leading bladder cancer company and we have jointly
agreed that the time is right for a commercially experienced CEO to lead the
company's next growth phase. I have enjoyed working with Kjetil and greatly
appreciates his contributions to the company over two decades. We wish him all
the best in his future endeavors", says Jan H. Egberts, Chairperson of the
Board.

"As Photocure is entering a phase with vast growth opportunities and an ambition
to expand the global commercial footprint, the timing is right to inform all
stakeholders that I will not lead Photocure in the company's next era. I am
proud of having been part of a company that has helped tens of thousands of
bladder cancer patients in fighting their disease. Photocure is a great company
with excellent people, world leading technology and products, and is perfectly
positioned to be a true industry leader within the field of bladder cancer",
says Kjetil Hestdal.

For further information, please contact:

Photocure
Jan Egberts
Chairperson of the Board
Tel: +31 614672518
Email: janegberts@aol.com

Notes to editors

About Photocure ASA

Photocure, The Bladder Cancer Company, delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, which makes
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo
Stock Exchange (OSE: PHO). The US headquarters for Photocure Inc., are in
Princeton, New Jersey. For more information, please visit us at
www.photocure.com, www.hexvix.com or www.cysview.com

This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.